Irlab: Missed primary endpoint in mesdopetam PD-LID phase IIb trial adds uncertainty - Redeye

Redeye lowers its valuation of Irlab following yesterday’s phase IIb top-line data with Mesdopetam in PD-LIDs, as the missed primary endpoint adds uncertainty to the future of mesdopetam. We will return with a research update in relation to the Q4 report in February.

Länk till analysen i sin helhet: https://www.redeye.se/research/871467/irlab-missed-primary-endpoint-in-mesdopetam-pd-lid-phase-iib-trial-adds-uncertainty?utm_source=finwire&utm_medium=RSS